Resolvin E1 regulates adenosine diphosphate activation of human platelets

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 10, 2010, Pages 2005-2013

  Fredman, Gabrielle ^a,b   Van Dyke, Thomas E ^b   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

adenosine diphosphate; eicosapentaenoic acid resolvin E1; inflammation; platelets

Indexed keywords

ACTIN; ADENOSINE DIPHOSPHATE; BETA ARRESTIN; CALCIUM ION; ICOSAPENTAENOIC ACID; PADGEM PROTEIN; RESOLVIN E1; UNCLASSIFIED DRUG; 5S,12R,18R-TRIHYDROXY-6Z,8E,10E,14Z,16E-EICOSAPENTAENOIC ACID; AUTACOID; CALCIUM; CHEMOKINE RECEPTOR; CMKLR1 PROTEIN, HUMAN; P2RY12 PROTEIN, HUMAN; PRIMER DNA; PURINERGIC P2 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; RECOMBINANT PROTEIN;

ACTIN POLYMERIZATION; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL TYPE; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; BLOOD; CELL LINE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HAMSTER; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

ACTINS; ADENOSINE DIPHOSPHATE; ANIMALS; BASE SEQUENCE; CALCIUM; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DNA PRIMERS; EICOSAPENTAENOIC ACID; HUMANS; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; P-SELECTIN; PLATELET ACTIVATION; PROTEIN MULTIMERIZATION; RECEPTORS, CHEMOKINE; RECEPTORS, PURINERGIC P2; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION; IN VITRO TECHNIQUES; RECEPTORS, PURINERGIC P2Y12;

EID: 77957698891     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.209908     Document Type: Article

References (53)

1. Majno G, Joris I. Cells, Tissues, and Disease: Principles of General Pathology. New York, NY: Oxford University Press; 2004.
2. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and Cotran Pathologic Basis of Disease. Philadelphia, PA: Elsevier/Saunders; 2005.
3. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140:871-882.
4. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov. 2004;3: 401-416.
5. Serhan CN. Endogenous chemical mediators in anti-inflammation and pro-resolution. Curr Med Chem Anti Inflamm Anti Allergy Agents. 2002; 1:177.
6. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192:1197-1204.
7. Van Dyke TE, Serhan CN. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res. 2003;82:82-90.
8. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 2008;22:3595-3606.
9. Wu SH, Liao PY, Yin PL, Zhang YM, Dong L. Inverse temporal changes of lipoxin A4 and leukotrienes in children with Henoch-Schonlein purpura. Prostaglandins Leukot Essent Fatty Acids. 2009;80:177-183.
10. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007;21:325-332.
11. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8:349-361.
12. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol. 2008;3:279-312.
13. Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ (Clin Res Ed). 2008;337:a2931.
14. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003;23:e20-e30.
15. Kasuga K, Yang R, Porter TF, Agrawal N, Petasis NA, Irimia D, Toner M, Serhan CN. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol. 2008;181: 8677-8687.
16. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196:1025-1037.
17. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005;201:713-722.
18. Haas-Stapleton EJ, Lu Y, Hong S, Arita M, Favoreto S, Nigam S, Serhan CN, Agabian N. Candida albicans modulates host defense by biosynthe-sizing the pro-resolving mediator resolvin E1. PLoS ONE. 2007;2:e1316.
19. Tjonahen E, Oh SF, Siegelman J, Elangovan S, Percarpio KB, Hong S, Arita M, Serhan CN. Resolvin e2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol. 2006;13:1193-1202.
20. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007;178:3912-3917.
21. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009;49:123-150.
22. Dona M, Fredman G, Schwab JM, Chiang N, Arita M, Goodarzi A, Cheng G, von Andrian UH, Serhan CN. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood. 2008;112:848-855.
23. Dasari VR, Jin J, Kunapuli SP. Distribution of leukotriene B4 receptors in human hematopoietic cells. Immunopharmacology. 2000;48:157-163.
24. Marcus AJ. Stratton lecture 1989: thrombosis and inflammation as mul-ticellular processes: pathophysiologic significance of transcellular metabolism. Blood. 1990;76:1903-1907.
25. Michelson AD. Platelets. Amsterdam, the Netherlands, and Boston, Mass: Academic Press/Elsevier; 2007.
26. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost. 2008;99:466-472.
27. Bhatt DL. Platelets in Cardiovascular Disease. London, England: Imperial College Press; 2008.
28. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010;9:154-169.
29. Arita M, Oh SF, Chonan T, Hong S, Elangovan S, Sun YP, Uddin J, Petasis NA, Serhan CN. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J Biol Chem. 2006;281: 22847-22854.
30. Hong S, Porter TF, Lu Y, Oh SF, Pillai PS, Serhan CN. Resolvin E1 metabolome in local inactivation during inflammation-resolution. J Immunol. 2008;180:3512-3519.
31. Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem. 2010;285:3451-3461.
32. Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, Nagura H, Saito H. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood. 1985;66: 1384-1392.
33. Marcet B, Chappe V, Delmas P, Verrier B. Pharmacological and signaling properties of endogenous P2Y1 receptors in cystic fibrosis trans-membrane conductance regulator-expressing Chinese hamster ovary cells. J Pharmacol Exp Ther. 2004;309:533-539.
34. Boccellino M, Biancone L, Cantaluppi V, Ye RD, Camussi G. Effect of platelet-activating factor receptor expression on CHO cell motility. J Cell Physiol. 2000;183:254-264.
35. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA. 2010;107: 1660-1665.
36. Olson KR, Eglen RM. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007;5:137-144.
37. Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun. 2005;337:281-288.
38. Fredman G. Resolvin E1 Regulation of Platelet Functions: Novel Pathways in Resolution [doctoral dissertation]. Boston, Mass: Department of Oral Biology, Boston University; 2009.
39. Paul BZ, Daniel JL, Kunapuli SP. Platelet shape change is mediated by both calcium-dependent and-independent signaling pathways: role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem. 1999;274:28293-28300.
40. Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood. 1998;92:152-159.
41. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999; 5:1199-1202.
42. Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999;104:1731-1737.
43. Communi D, Janssens R, Suarez-Huerta N, Robaye B, Boeynaems JM. Advances in signalling by extracellular nucleotides: the role and transduction mechanisms of P2Y receptors. Cell Signal. 2000;12:351-360.
44. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the platelet ADP receptor targeted by thienopy-ridine antithrombotic drugs. J Clin Invest. 2001;107:1591-1598.
45. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood. 1992;80:2787-2796.
46. Hardy AR, Conley PB, Luo J, Benovic JL, Poole AW, Mundell SJ. P2Y1 and p2y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood. 2005;105:3552-3560.
47. Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci. 2007;28:416-422.
48. Samuelsson B. Leukotrienes: a novel group of compounds including SRS-A. Prog Lipid Res. 1981;20:23-30.
49. Paruchuri S, Tashimo H, Feng C, Maekawa A, Xing W, Jiang Y, Kanaoka Y, Conley P, Boyce JA. Leukotriene e4-induced pulmonary inflammation is mediated by the p2y12 receptor. J Exp Med. 2009;206:2543-2555.
50. Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977;1:18-20.
51. Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggers intracoronary leukotrienes and lipoxin A4: impact of aspirin therapy. Circulation. 1992;86:56-63.
52. Wilson SJ, Roche AM, Kostetskaia E, Smyth EM. Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem. 2004; 279:53036-53047.
53. Wilson SJ, Dowling JK, Zhao L, Carnish E, Smyth EM. Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells: role of receptor heterodimerization. Arte-rioscler Thromb Vasc Biol. 2007;27:290-296.